Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
Abstract Serum neurofilament light chain (NfL) is emerging as an important biomarker in multiple sclerosis (MS). Our objective was to evaluate the prognostic value of serum NfL levels obtained close to the time of MS onset with long-term clinical outcomes. In this prospective cohort study, we identi...
Guardado en:
Autores principales: | Simon Thebault, Mohammad Abdoli, Seyed-Mohammad Fereshtehnejad, Daniel Tessier, Vincent Tabard-Cossa, Mark S. Freedman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/dc8ebacfb861461997465aea745bc483 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
por: Paulette Esperanza Walo-Delgado, et al.
Publicado: (2021) -
Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study
por: Cai L, et al.
Publicado: (2018) -
Serum neurofilament light chain as a severity marker for spinocerebellar ataxia
por: Hye-Rim Shin, et al.
Publicado: (2021) -
Seven day pre-analytical stability of serum and plasma neurofilament light chain
por: Patrick Altmann, et al.
Publicado: (2021) -
Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
por: Marta Simone, et al.
Publicado: (2021)